The Lancet: March 25, 2008
Josef Smolen from the Medical University of Vienna, Austria, discusses in this week's podcast how the monoclonal antibody tocilizumab could be effective in treating rheumatoid arthritis. Tocilizumab blocks interleukin 6, a pro-inflammatory cytokine involved in the biological process behind rheumatoid arthritis
Source: Listen to The Lancet - Category: General Medicine Authors: The Lancet Source Type: podcasts
More News: Actemra | Arthritis | Austria Health | General Medicine | Podcasts | Rheumatoid Arthritis | Rheumatology